Request the brochure

* Denotes Required Field
Theme: Discover the Latest R&D, Technical and Commercial Strategies Driving the Precision Medicine and Cell Therapy Revolution in China
As the trend of biopharma development, precision medicine has attracted different countries to capitalize on it. Gene sequencing is seen as the foundation of precision medicine and thanks to its technological breakthrough in oncology diagnostics, precision medicine has developed at a rapid rate. Meanwhile, sectors related to precision medicine like cell therapy, liquid biopsy, antibody drugs, big data, gene chips, PCR are pursued by capitals. There are 26 listed companies in China in gene sequencing, cell therapy and stem cell business with 20% + CAGR. With increasing professional level for precision medicine, it is expected to become a market with billions of dollar market size. Curing cancers have come become the core part of PMI for different countries due to the rising incidence of cancer and associated medical expenditure. Based on authoritative report, the global market size for cancer immunotherapy will grow to roughly USD 100 billion in 2021 from USD 620 billion in 2016 with 14% CAGR. PD-L1/PD-1 antibody has demonstrated good market prospect. Besides, cellular therapy has attracted global attention. Based on statistics, there’re 173 ongoing CAR-T clinical trials in the world and China ranks 2nd next to US with 30 clinical trials and 24 targets. Experts think with advancements in gene diagnostics and immunotherapy, cell based combination therapy could be hu Read more...

Eminent Speakers

Jin LI, Director, Department of Medical Oncology,

Shanghai East Hospital affiliated to Tongji University, Shanghai China

Xin ZHANG, Deputy Director of Respiratory Department

Shanghai ZhongShan Hospital Fudan University

Zhou YUAN, Head of General Surgery

Sixth People’s Hospital Shanghai Jiao Tong University

Baorui LIU, Director of Cancer Department

Nanjing Drum Tower Hospital, Nanjing U. Medical School

Lunxiu QIN, Associate Dean & Head of Surgery

Huanshan Hospital

Mingqiang ZHANG, Vice President

Amgen Biopharmaceutical

Min HU, Principal Scientist, Genetics Team Leader Biomarker, Asia & Emerging Markets iMed,

AstraZeneca China

Danyi WEN, CEO & President

LIDE Biotech

Robert CHEN, Vice President

Genor Biopharma

Li YIN, ADC Senior R&D Director

Wuxi Apptec

Yinkun LIU, PI, Professor, Deputy Director of Liver Cancer Research Institute,

Zhongshan Hospital Fudan Univeristy

Pengyuan YANG, Ph.D., Prof. Principal Investigator

Institute of Biophysics, CAS

Weidong HAN, Director of Dept. of Molecular and Cellular Biology, Director of Clinical Translational

Ward, Chinese PLA General Hospital

Cheng QIAN, Director of the Bio-Treatment Center

Southwest Hospital affiliated to Third Military Medical University

Alex Chang, Visiting Professor

Tongji University School of Medicine

Zeguang HAN, Professor, Executive Vice-Dean, Center for Systems Biomedicine

Shanghai Jiao Tong University

Lei LIU, Professor

Biomedical Research Institute of Fudan University

Shengying QIN, Professor

The Bio-X Institutes of Shanghai Jiao Tong University

Event Features

  • 300+ delegates from over 10 countries and regions
  • 100+ attending organizations
  • 40+ eminent speakers from academia, pharma, hospital
  • 70% on average attendees from primary market (hospitals, academia, biopharma etc)
  • 60% above company decision making and director level
  • 1 main conference and 4 focused streams

Key Topics

  • Key opportunities and risks for China’s precision medicine industry in 2017/18
  • Innovation and Collaboration in Precision Medicine in China
  • Application big data, cloud computing and other innovative technologies in PM
  • How biobanks contribute to translational research and precision Medicine
  • How big pharma are implementing biomarkers in their cancer immunotherapy clinical strategy
  • Asian and China's key VCs perspective on the keys to winning the battle for investment in precision medicine

Summit Supporters

Produced by
Media Partners